Language
English
Publication Date
4-11-2024
Journal
Research Square
DOI
10.21203/rs.3.rs-4232549/v1
PMID
38659815
PMCID
PMC11042400
PubMedCentral® Posted Date
4-11-2024
PubMedCentral® Full Text Version
Pre-Print
Abstract
We report long-term outcomes up to 18 years of a clinical trial treating children with neuroblastoma with EBV-specific T lymphocytes and CD3-activated T cells - each expressing a first-generation chimeric antigen receptor targeting GD2 with barcoded transgenes to allow tracking of each population. Of 11 patients with active disease at infusion, three patients achieved a complete response that was sustained in 2, one for 8 years until lost to follow up and one for 18+ years. Of eight patients with a history of relapse or at high risk of recurrence, five are disease-free at their last follow-up between 10-14 years post-infusion. Intermittent low levels of transgene were detected during the follow up period with significantly greater persistence in those who were long-term survivors. In conclusion, patients with relapsed/refractory neuroblastoma achieved long-term disease control after receiving GD2 CAR-T cell therapy including one patient now in remission of relapsed disease for >18 years.
Published Open-Access
yes
Recommended Citation
Che-Hsing, Li; Sharma, Sandhya; Heczey, Andras A; et al., "Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma" (2024). Faculty, Staff and Students Publications. 8826.
https://digitalcommons.library.tmc.edu/baylor_docs/8826